Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2018 April;59(2) > The Journal of Cardiovascular Surgery 2018 April;59(2):232-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE  VASCULAR SECTION Freefree

The Journal of Cardiovascular Surgery 2018 April;59(2):232-6

DOI: 10.23736/S0021-9509.18.10269-2

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Lutonix® 014 DCB global Below the Knee Registry Study: interim 6-month outcomes

Marcus THIEME 1 , Michael LICHTENBERG 2, Marianne BRODMANN 3, Angelo CIOPPA 4, Dierk SCHEINERT 5

1 Department of Angiology/Cardiology/Diabetology, Regiomed-Vascular Center, Sonneberg, Germany; 2 Klinik für Angiologie, Klinikum Arnsberg, Arnsberg, Germany; 3 Clinical Division of Angiology, Medical University Graz, Graz, Austria; 4 Invasive Cardiology Laboratory, Cardiology Division, Clinica Montevergine, Mercogliano, Avellino, Italy; 5 Klinik und Poliklinik für Angiologie, Universitätsklinikum Leipzig, Leipzig, Germany


PDF


BACKGROUND: The most common clinical presentation of peripheral artery disease (PAD) comprises intermittent claudication (IC), but about one third of patients will progress to critical limb ischemia (CLI), characterized by rest pain and/or tissue loss, which is the most severe limb manifestation of PAD. Paclitaxel-coated balloons are well established for the endovascular treatment of femoropopliteal lesions in patients with IC and CLI. This ongoing multicenter registry study is exploring the role of the Lutonix® 014 drug-coated balloon (DCB) in the treatment of below-the-knee (BTK) arteries and CLI.
METHODS: Three hundred fourteen (314) patients were enrolled from 26 sites and 12 countries. The real-world patients represent those undergoing intervention for BTK arteries with the Lutonix® 014 DCB. The study had both, primary safety and primary efficacy endpoints. The primary safety endpoint was freedom at 30 days from BTK major adverse limb event (MALE) + perioperative death (POD). Primary efficacy was freedom from clinically driven target lesion reintervention (fTLR) at 6 months. Additional secondary endpoints related to safety were reported.
RESULTS: The interim 6 months’ results showed freedom from MALE and POD at 30 days of 98.6% and at 6 months (180 days) of 96.0%. Primary efficacy of fTLR at 6 months (180 days) was 87.9%. Safety related secondary endpoints at 6 months (180 days) showed freedom from all of the following: all cause death of 91.2%, above ankle amputation 97.1%, reintervention for thrombosis 95.2%, reintervention for distal embolization 100.0%, and target vessel revascularization of 88.0%. There were no unexpected device or drug related events reported.
CONCLUSIONS: The interim 6-month outcomes demonstrate the safety and efficacy of the Lutonix® 014 DCB for the treatment of BTK arteries.


KEY WORDS: Angioplasty, balloon - Atherosclerosis - Device approval - Paclitaxel

inizio pagina